A window into immunosuppressant immunoregulation: recipient conversion to rapamycin increases potentially tolerogenic immune cells.
other · Level V
Where this comes from
- Record sourced from PubMed, PMID 24682122.
- Also identified by DOI 10.1038/ki.2013.420.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mechanistic target of rapamycin inhibitors (mTORi) have a complex immunoregulatory profile in both animal models and transplant patients. Studies suggest that mTORi act as tolerance-supporting and regulatory T cell (Treg)-promoting immunosuppressants. Yet proinflammatory influences on myeloid dendritic cells have been established. Insight is needed into the impact of mTORi on immune cells. Stallone et al. describe a clinical study identifying a potential immunoregulatory pathway involving plasmacytoid dendritic cells and Tregs in renal transplant patients on mTORi.
Medical subject headings
- Dendritic Cells
- Immunosuppressive Agents
- Sirolimus
- T-Lymphocytes